Abstract
The outlook for patients with mantle cell lymphoma is poor. The reported median survival in most published series is only 3 to 4 years, and even the most favorable prognostic groups have median survival rates of only 5 years, with no evidence of cure. The use of autologous and allogeneic stem cell transplantation in this disease has increased dramatically in recent years. Despite encouraging reports from single centers and registries, the impact of stem cell transplantation on the outcome for mantle cell lymphoma is unclear. Optimal first-line regimens for mantle cell lymphoma have yet to be defined, and it is therefore difficult to place the role of first remission transplantation in an appropriate context. Prospective randomized trials have been difficult to design and conduct in the absence of a well-defined ‘standard’ treatment. The role of stem cell transplantation as a salvage strategy is also unknown, although available data suggest that it does not improve survival in heavily pre-treated patients. In the absence of clear evidence for a survival advantage for patients receiving stem cell transplants for mantle cell lymphoma, entry into clinical trials should be a priority. Bone Marrow Transplantation (2001) 28, 813–820.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Stewart DA, Vose JM, Weisenberger DD et al. The role of high-dose therapy and autologous hematopoietic stem cell transplantation for mantle cell lymphoma Ann Oncol 1995 6: 263–266
Haas R, Brittinger G, Meusers P et al. Myeloablative therapy with blood stem cell transplantation is effective in mantle cell lymphoma Leukemia 1996 10: 1975–1979
Dreger P, von Neuhoff N, Kuse R et al. Sequential high-dose therapy and autologous stem cell transplantation for treatment of mantle cell lymphoma Ann Oncol 1997 8: 401–403
Ketterer N, Salles G, Espinouse D et al. Intensive therapy with peripheral stem cell transplantation in 16 patients with mantle cell lymphoma Ann Oncol 1997 8: 701–704
Kroger N, Hoffneckht M, Dreger P et al. Long-term disease-free survival of patients with advanced mantle-cell lymphoma following high-dose chemotherapy Bone Marrow Transplant 1998 21: 55–57
Blay J-Y, Sebban C, Surbiguet C et al. High-dose chemotherapy with hematopoietic stem cell transplantation in patients with mantle cell or diffuse centrocytic non-Hodgkin's lymphomas: a single center experience on 18 patients Bone Marrow Transplant 1998 21: 51–54
Milpied N, Gaillard F, Moreau P et al. High-dose therapy with stem cell transplantation for mantle cell lymphoma: results and prognostic factors, a single center experience Bone Marrow Transplant 1998 22: 645–650
Freedman AS, Neuberg D, Gribben JG et al. High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle cell lymphoma: no evidence for long-term remission J Clin Oncol 1998 16: 13–18
Khouri IF, Romaguera J, Kantarjian H et al. Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem cell transplantation: an active regimen for aggressive mantle cell lymphoma J Clin Oncol 1998 16: 3803–3809
Vose JM, Bierman PJ, Weisenberger DD et al. Autologous hematopoietic stem cell transplantation for mantle cell lymphoma Biol Blood Marrow Transplant 2000 6: 640–645
Decaudin D, Brousse N, Brice P et al. Efficacy of autologous stem cell transplantation in mantle cell lymphoma: a 3 year follow up study Bone Marrow Transplant 2000 25: 251–256
Corradini P, Ladetto M, Astolfi M et al. Clinical and molecular remission after allogeneic blood cell transplantation in a patient with mantle cell lymphoma Br J Haematol 1996 94: 376–378
Kroger N, Hoffnecht M, Kruger W et al. Allogeneic bone marrow transplantation for refractory mantle cell lymphoma Ann Hematol 2000 79: 578–580
Martinez C, Carreras E, Rovira M et al. Patients with mantle cell lymphoma relapsing after autologous stem cell transplantation may be rescued by allogeneic transplantation Bone Marrow Transplant 2000 26: 677–679
Khouri IF, Lee M-S, Romaguera J et al. Allogeneic hematopoietic transplantation for mantle cell lymphoma: molecular remissions and evidence of graft-versus-malignancy Ann Oncol 1999 10: 1293–1299
Harris NL, Jaffe ES, Stein H et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group Blood 1994 84: 1361–1392
Harris NL, Jaffe ES, Diebold J et al. The World Health Organization Classification of Diseases of the Hematopoietic and Lymphoid Systems Ann Oncol 1999 10: 1419–1432
Zucca E, Stein H, Coiffer B . European Lymphoma Task force (ELTF): report of the workshop on mantle cell lymphoma (MCL) Ann Oncol 1994 5: 507–511
Fisher RI, Dahlberg S, Nathwani BN et al. A clinical analysis of two indolent lymphoma entities: mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories): a Southwest Oncology Group study Blood 1995 85: 1075–1082
Teodorovic I, Pittaluga S, Kluin-Nelemans JC et al. Efficacy of four different regimens in 64 mantle-cell lymphoma cases: clinicopathologic comparison with 498 other non-Hodgkin's lymphoma subtypes J Clin Oncol 1995 13: 2819–2826
Norton AJ, Matthews J, Pappa V et al. Mantle cell lymphoma: Natural history defined in a serially biopsied population over a 20-year period Ann Oncol 1995 6: 249–256
Velders GA, Kluin-Nelemans JC, De Boer CJ et al. Mantle-cell lymphoma: a population-based study J Clin Oncol 1996 14: 1269–1274
Zucca E, Roggero E, Pinotti G et al. Patterns of survival in mantle cell lymphoma Ann Oncol 1996 6: 257–262
Weisenberger DD, Armitage JO . Mantle cell lymphoma – an entity comes of age Blood 1996 87: 4483–4494
Majlis A, Pugh WH, Rodriguez MA et al. Mantle cell lymphoma: correlation of clinical outcome and biologic features with three histologic variants J Clin Oncol 1997 15: 1664–1671
Montserrat E, Bosch F, Lopez-Guillermo A et al. CNS involvement in mantle cell lymphoma J Clin Oncol 1996 14: 941–944
Argatoff LH, Connors JM, Klasa RJ et al. Mantle cell lymphoma: a clinicopathologic study of 80 cases Blood 1997 89: 2067–2078
Oinonen R, Franssila K, Teerenhovi et al. Mantle cell lymphoma: clinical features, treatment and prognosis of 94 patients Eur J Cancer 1998 34: 329–366
Bosch F, Lopez-Guillermo A, Campo E et al. Mantle cell lymphoma. Presenting features, response to therapy and prognostic factors Cancer 1998 82: 567–575
Weisenberger DD, Vose JM, Greiner TC et al. Mantle cell lymphoma. A clinicopathologic study of 68 cases from the Nebraska Lymphoma Study Group Am J Hematol 2000 64: 190–196
Vandenberghe E, De Wolf-Peeters C, Vaughan-Hudson G et al. The clinical outcome of 65 cases of mantle cell lymphoma initially treated with non-intensive therapy by the British National Lymphoma Investigation Group Br J Haematol 1999 99: 842–847
Foran JM, Rohatiner AZS, Cunningham D et al. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle cell lymphoma and previously treated mantle cell lymphoma, immunocytoma and small B-cell lymphocytic lymphoma J Clin Oncol 2000 18: 317–324
Foran JM, Cunningham D, Coiffier B et al. Treatment of mantle cell lymphoma with rituximab (chimeric monoclonal anti-CD20 antibody): analysis of factors associated with response Ann Oncol 2000 11: (Suppl. 1) 117–121
Howard O, Gribben JG, Neuberg D et al. Rituxan/CHOP induction therapy in newly diagnosed patients with mantle cell lymphoma Blood 1999 94: 631a (Abstr.)
Hernandez L, Fest T, Cazorla M et al. P53 gene mutations and protein overexpression are associated with aggressive variants of mantle cell lymphomas Blood 1996 87: 3351–3359
Greiner TC, Moynihan MJ, Chan WC et al. P53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis Blood 1996 87: 4302–4310
Yatabe Y, Suzuki R, Tobinai K et al. Significance of cyclin D1 overexpression for the diagnosis of mantle cell lymphoma: a clinicopathologic comparison of cyclin D1-positive and cyclin D1-negative MCL-like B-cell lymphoma Blood 2000 95: 2253–2261
The International Non-Hodgkin's Lymphoma Prognostic Factors Project: a predictive model for aggressive non-Hodgkin's lymphoma New Engl J Med 1993 329: 987–994
Armitage JO, Weisenberger DD . New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes J Clin Oncol 1998 16: 2780–2795
Vandenberghe E, Ruiz de Elvira C, Isaacson P et al. Does transplantation improve outcome in mantle cell lymphoma (MCL)? A study from the EBMT Blood 2000 96: 482a (Abstr.)
Malone JM, Molina A, Stockerl-Goldstein K et al. High dose therapy and autologous hematopoietic cell transplantation for mantle cell lymphoma: the Stanford/City of Hope experience Proc Am Soc Clin Oncol 2001 20: 13a (Abstr.)
The Non-Hodgkin's Lymphoma Classification Project . A clinical evaluation of the International Lymphoma Study Group Blood 1997 89: 3909–3918
Romaguera JE, Dang NH, Hagemeister FB et al. Preliminary report of rituximab with intensive chemotherapy for untreated aggressive mantle cell lymphoma (MCL) Blood 2000 96: 733a (Abstr.)
Jacquy C, Lambert F, Soree A et al. Peripheral blood stem cell contamination in mantle cell non-Hodgkin lymphoma: the case for purging? Bone Marrow Transplant 1999 23: 681–686
Andersen NS, Donovan JW, Borus JS et al. Failure of immunologic purging in mantle cell lymphoma assessed by polymerase chain reaction detection of minimal residual disease Blood 1997 90: 4212–4221
Foran JM, Gupta RK, Cunningham D et al. Immunotherapy of follicular lymphoma with rituximab (chimeric anti-CD20 monoclonal antibody): a UK phase II trial with monitoring of molecular response Br J Haematol 2000 109: 81–88
Magni M, Di Nicola M, Devizzi L et al. Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence foe a role of both chemotherapy and rituximab infusion Blood 2000 96: 864–869
Van Besien KW, De Lima M, Giralt S et al. Management of lymphoma recurrence after allogeneic transplantation: the relevance of graft-versus-lymphoma effect Bone Marrow Transplant 1997 19: 977–982
Rondon G, Giralt S, Huh Y et al. Graft-versus- leukemia after allogeneic bone marrow transplantation for chronic lymphocytic leukemia Bone Marrow Transplant 1996 18: 669–672
Khouri IF, Keating M, Korbling M et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies J Clin Oncol 1998 16: 2817–2824
Sohn SK, Bensinger W, Holmberg L et al. High-dose chemotherapy with allogeneic or autologous stem cell transplantation for relapsed mantle cell lymphoma: the Seattle experience Proc Am Soc Clin Oncol 1997 17: 17a (Abstr.)
Adkins D, Brown R, Goodnough LT et al. Treatment of resistant mantle cell lymphoma with allogeneic bone marrow transplantation Bone Marrow Transplant 1998 21: 97–99
Molina A, Nademanee A, O'Donnell MR et al. Autologous and allogeneic stem-cell transplantation for poor-risk mantle cell lymphoma: the City of Hope experience Blood 1998 92: 459a (Abstr.)
Sohn SK, Baek JH, Kim DH et al. Successful allogeneic stem-cell transplantation with prophylactic stepwise G-CSF primed DLIs for relapse after autologous transplantation in mantle cell lymphoma: a case report and literature review on the evidence of GVL effects in MCL Am J Hematol 2000 65: 75–80
Press OW, Eary JF, Gooley T et al. A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas Blood 2000 96: 2934–2942
King CA, Spellerberg MB, Ziiu D et al. DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma Nat Med 1998 4: 1281–1286
Acknowledgements
The author wishes to acknowledge the assistance of the Statistical Center of the International Bone Marrow Transplant Registry and the Autologous Blood and Marrow Transplant Registry who provided details of transplant activity in mantle cell lymphoma, and Dr Hillard M Lazarus for his critical review of this manuscript.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sweetenham, J. Stem cell transplantation for mantle cell lymphoma: should it ever be used outside clinical trials?. Bone Marrow Transplant 28, 813–820 (2001). https://doi.org/10.1038/sj.bmt.1703255
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1703255